DAFTAR PUSTAKA

1. Gudjonsson JE, Elder JT. Psoriasis. Dalam: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editor. Fitzpatricks Dermatology in General Medicine. Edisi ke-7. New York. McGraw-Hill;2008. h.169-193.

2. Langley R, Krueger G, Griffiths C. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64:ii18-ii23.

3. Neimann A, Porter S, Gelfand J. The epidemiology of psoriasis. Expert Rev. Dermatol. 2006;1(1), 63-75.

4. Damasiewicz A, Kuda B. Hormonal factors in etiopathogenesis of psoriasis. Pol Merkur Lekarski. 2007;22(127):75-8.

5. Foitzik K, Langan E, Paus R. Prolactin and the skin: A dermatological perspective on an ancient pleiotropic peptide hormone. Journal of investigative dermatology 2009;129:1071-87.

6. Guyton A, Hall J. Hormon-hormon hipofisis dan pengaturannya oleh hipotalamus. Buku Ajar Fisiologi Kedokteran. Edisi ke-11. Indonesia. EGC;2006. h.964-991.

7. Freeman E, Kanyicska B, Lerant A. Prolactin: structure, function, and regulation of secretion. Physiological reviews 2000;80:4.

8. Yuan L, Lee Y. Prolactin modulation of immune and inflammatory response. Endocrinology 2002;57:435-55.

9. Weber G, Neidhardt M, Frey H, Galle K, Geiger A. Treatment of psoriasis with bromocriptin. Arch Dermatol Res. 1981;271:4379

10. Dunna SF, Finlay AY. Psoriasis, improvement during and worsening after pregnancy. Br J Dermatol.1989;120:584

11. Giasuddin AS, El-Sherif AI, El-Ojali SI. Prolactin: does it have a role in the pathogenesis of psoriasis?. Dermatology 1998;197:11922

12. Azzizadeh M, Malek M, Amiri M. Does prolactin indicate severity of psoriasis?. Iranian journal of dermatology 2009;12:3.

13. Dilme E, Martin G, Regana M. Serum prolactin levels ini psoriasis and correlation with cutaneous disease activity. Clinical and experimental dermatology 2010;36:29-32.

14. Sanchez RM, Umbert MP. Psoriasis in association with prolactinoma: three cases. Br J Dermatol. 2000;143:8647

15. Gorpeligolu C, Gungor E, Alli N. Is prolactin involved in etiopathogenesis of psoriasis? J Eur Acad Dermatol Venereol. 2008;22:1135-6.

16. Das R, Jain A, Ramesh V. Current concepts in pathogenesis of psoriasis. Indian J Dermatol. 2009;54(1):7-12.

17. Blauvelt A. New concept in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF-1. Expert Rev. Dermatol. 2007;2(1), 69-78.

Universitas Sumatera Utara

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Damasiewicz-Bodzek%20A%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Kos-Kud%C5%82a%20B%22%5BAuthor%5D

18. Bettina M, Vavricka P, Guitart J. Diagnostic evaluation. Psoriatis and Psoriatic Arthritis- An Integrated Approach. Edisi ke-1. New York. Springer;2005. h.83-91.

19. Lisi P. Differential diagnosis of psoriasis. Reumatismo 2007;59:5660.

20. Lionel F. Differential diagnosis. An Atlas of Psoriasis. Edisi ke-2. London. Taylor & Francis;2004. h.67-69.

21. Meier M, Sheth P. Clinical spectrum and severity of psoriasis. Curr Probl Dermatol. Basel. 2009;38:120.

22. Feldman S, Krueger G. Psoriasis assesment tools in clinical trial. Ann Rheum. Dis. 2005;64:ii65-ii68.

23. Kenneth B. Clinical outcome measurements. Psoriatis and Psoriatic Arthritis- An Integrated Approach. Edisi ke-1. New York. Springer;2005. h.125-128.

24. Bonifati C, Berardesca E. Clinical outcome measures of psoriasis. Reumatismo 2007;59 :64-67.

25. Traub M, Marshall K. Psoriasis pathophysiology, conventional and alternative approaches to treatment. Alternative Medicine Review 2007;12:319-30.

26. Reich K, Mrowietz U. Treatment goal in psoriasis. JDDG. 2007;5:566574.

27. Sullivan J. Treatment for severe psoriasis. Aust Prescr. 2009;32:1418.

28. Harvey J, Guyda, Friesen H. Serum prolactin levels in humans from birth to adult life. Pediat. Res.1973;7:534-40.

29. Frantz AG. Prolactin. N Engl J Med. 1978;298: 201207. 30. Franklin Scientific Projects Ltd. Normal and pathological prolactin

levels. Clear Perspectives 1996;3:1-4. 31. Paus R, Theoharides TC, Arck PC. Neuroimmunoendocrine

circuitry of the brainskin connection. Trends Immunol. 2006;27:329.

32. Girolomoni G, Phillips JT, Bergstresser PR. Prolactin stimulates proliferation of cultured human keratinocytes. J Invest Dermatol. 1993;101:2759.

33. Yu-Lee L. Stimulation of interferon regulatory factor-1 by prolactin. Lupus 2001;10:6919.

34. De Bellis A, Bizzarro A, Pivonello R, Lombardi G, Bellastella A. Prolactin and autoimmunity. Pituitary 2005;8:2530.

35. Biswas R, Roy T, Chattopadhyay U. Prolactin induced reversal of glucocorticoid mediated apoptosis of immature cortical thymocytes is abrogated by induction of tumor. J Neuroimmunol. 2006;171:12034.

36. Carreno PC, Jimenez E, Sacedon R, Vicente A, Zapata AG. Prolactin stimulates maturation and function of rat thymic dendritic cells. J Neuroimmunol. 2004;153:8390.

37. Matera L, Mori M, Galetto A. Effect of prolactin on the antigen presenting function of monocyte-derived dendritic cells. Lupus 2001;10:72834.

Universitas Sumatera Utara

38. Sun R, Li AL, Wei HM, Tian ZG. Expression of prolactin receptor and response to prolactin stimulation of human NK cell lines. Cell Res. 2004;14:6773

39. Malaguarnera L, Imbesi R, Di Rosa M, Scuto A et al. Action of prolactin, IFN-gamma, TNF-alpha and LPS on heme oxygenase-1 expression and VEGF release in human monocytes/macrophages. Int Immunopharmacol. 2005;5:145869.

40. Kanda N, Watanabe S. Prolactin enhances interferon- induced production of CXCL9, CXCL10, and CXCL11. Endocrinology 2007;148:231725.

41. Kanda N, Shibata S, Tada Y et al. Prolactin enhances basal and IL-17 induced CCL20 production by human keratinocytes. Eur J Immunol. 2009;39(4):996-1006.

42. Murase J, Chan K, Garite T et al. Hormonal effect of psoriasis in pregnancy and post partum. Arch Dermatol. 2005;141:601-606.

43. Raychaudhuri S, Navare T, Gross J et al. Clinical course of psoriasis during pregnancy. International Journal of Dermatology 2003;42:518520.

44. Griffiths CE, Katsambas A, Dijkmans BA et al. Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol. 2006;155:116.

45. Suite M. The epidemiology of psoriasis in a dermatology clinic in a general hospital in port of Spain, Trinidad and Tobago, West Indies. West Indian Med J. 2006;55(6):1.

46. Naldi L. Epidemiology of psoriasis.Curr Drug Target Inflamm Allergy. 2004;3(2):121-8.

47. Fatani MI, Abdulghani MH, Al-Afif KA. Psoriasis in the eastern saudi arabia. Saudi Med J. 2002;23(2):213-7.

48. Dogra S, Yadav S. Psoriasis in India: prevalence and pattern. Indian J Dermatol Venereol Leprol 2010;76:595-60.

49. Mabuchi T, Yamaoka H, Kojima T et al. Psoriasis affects patient quality of life more seriously in female than male in Japan. Tokai J Exp Clin Med. 2012;37(3):84-8.

50. Gupta MA, Gupta KA. Age and gender differences in the impact of psoriasis on quality of life. Int J Dermatol. 1995;34:700-703.

51. Jacobson CC, Kimball AB. Epidemiology. Dalam: Kenneth B, editor. Psoriasis and Psoriatic Arthritis- An Integrated Approach. Edisi ke-1. New York. Springer;2005. h.125-128.

52. Inerot A, Enerback C, Enlund et al. Collecting a set of psoriasis family material through a patient organization; clinical characterization and presence of additional disorders. BMC Dermatology. 2005;5(10):1-8.

Universitas Sumatera Utara

http://www.ncbi.nlm.nih.gov/pubmed?term=Fatani%20MI%5BAuthor%5D&cauthor=true&cauthor_uid=11938399http://www.ncbi.nlm.nih.gov/pubmed?term=Abdulghani%20MH%5BAuthor%5D&cauthor=true&cauthor_uid=11938399http://www.ncbi.nlm.nih.gov/pubmed?term=Al-Afif%20KA%5BAuthor%5D&cauthor=true&cauthor_uid=11938399